What Researchers Did
Researchers conducted a narrative review to summarize past clinical and experimental studies on the role of hyperbaric oxygen therapy (HBOT) in inflammatory bowel disease (IBD).
What They Found
The review found that hyperbaric oxygen therapy (HBOT) has been reported as an adjunct to conventional medical treatment for refractory inflammatory bowel disease (IBD). Clinical and experimental studies suggest HBOT may work by inhibiting inflammation, strengthening the antioxidant system, promoting colonic stem cell differentiation, and recruiting repair cells.
What This Means for Canadian Patients
Canadian patients with inflammatory bowel disease (IBD) may eventually benefit from hyperbaric oxygen therapy (HBOT) as an adjunctive treatment, particularly for refractory cases. This therapy could offer a new approach to managing symptoms by targeting inflammation and promoting tissue repair in the digestive tract.
Canadian Relevance
This narrative review does not have a direct Canadian connection.
Study Limitations
As a narrative review, this study summarizes existing literature without providing a systematic analysis or quantitative synthesis of the evidence.